LOS ANGELES, Sept. 12, 2013 /PRNewswire/ -- Dr. Rongxiang Xu, US Patent Owner of "Damaged Organ Regeneration" Scientific Route Promoted by President Obama, the founder of "human body regenerative restoration science" and a renowned life and medical scientist has announced he has been granted a new patent (Priority: US10/004,103, Oct 30, 2001; Patent Number: ZL200610153824.8) by the State Intellectual Property Office of P.R.China (SIPO) for his invention called "Potential Regenerative Cell" (PRC), which means the affirmation of the existence and function of PRC in the human body and further verification of the innate human regenerative potential and its origin. Dr. Xu has been granted multiple patents (including US6991813) in the United States since 2004 for his scientific route and platform patent application of "culturing PRCs into pluripotent stem cells and regenerate damaged organs," whereby the route of "damaged organ regeneration" was noted as a priority of life science development in Obama's 2013 Presidential State of the Union address.
PRCs in the human body are adult tissue cells which can convert to the functional state of pluripotent stem cells; PRCs can convert into pluripotent stem cells under in vitro or in vivo cultivation; PRCs can be awakened, in situ or in vitro, to present the function of pluripotent stem cells and regenerate functional tissue-organs. "Potential Regenerative Cell" is a revolutionary invention in human life science development.
"PRC" is the latent regenerative life entity in the human body. By awakening and nourishing its function, each human organ can generate its own regenerative life, using its own regenerative capacity to protect, save, restore and rejuvenate itself, a process that until Dr. Xu's invention, was not deemed possible. Enabling "PRC" to take effect by cultivation in the human body has been practically applied gradually for 29 years, with thousands of burn and ulcer patients being saved in 73 countries. Regenerative restoration of diseased human internal organs and regenerative rejuvenation of aging organs has occurred in numerous countries. "The purpose of the 'Announcement for accomplished organ regeneration technologies in humans' that I released in June 2013 was to inform the public of the scientific technologies that are available to regenerate and restore damaged or aging organs," stated Dr. Xu.
The patent applications of "Potential Regenerative Cell" and "damaged organ regeneration scientific route" belong to the same patent platform filed application with priority in the US in 2002. According to Dr. Xu's strategy for protecting his intellectual property, the substantial examination of the patent application for the scientific route of organ regeneration accomplished by PRCs was first filed with the United States Patent and Trademark Office ("USPTO") in 2002, his patent application of Potential Regenerative Cell was filed with SIPO of China for substantial examination in 2002. Around 2005-2006, the USPTO granted multiple patents to Dr. Xu for the culture method of PRCs and the scientific route of "in situ conversion of PRCs to pluripotent stem cells regenerating physiological tissues and organs". In contrast, SIPO of China decided to organize a specific committee to conduct strict scrutiny of PRCs for its proclaimed reason that, in the history of life science, there was no reference information available for the term and functionality of "Potential Regenerative Cell" applied by Dr. Xu. From affirmation to negation and to affirmation again, the SIPO has continued scrupulous review and gone through an 11-year debate with Dr. Rongxiang Xu, and eventually granted the patent on August. 28, 2013, affirming the existence and function of PRC in the human body which stands for the discovery and invention of a type of somatic cells in the human body which can exert the function of pluripotent stem cells. By applying Dr. Xu's cultivated process humankind can directly awaken this type of cells to exert pluripotent stem cell's function to restore an organ whenever it is damaged or diseased which would confer the utmost benefit to humanity.
In order for the public to comprehend the scientific contribution of the benefits of PRCs, Dr. Xu provided further explanation to the following questions:
Q. What is the difference between "PRC" and the concept of human stem cell?
A. As depicted in the stem cell primer (NIH, May 2000), stem cells are those cells which can always maintain the function of proliferation and differentiation during embryonic development and after birth of the human body. Those able to develop into the whole human body are totipotent stem cells; those only able to develop into physiological tissues and organs are pluripotent stem cells; and those continuing to present the function of proliferation and differentiation after birth are adult stem cells.
In contrast, "PRC" is a somatic cell existing in the tissues of adult human organs. As an ordinary tissue cell, "PRC" usually does not present the function of proliferation and differentiation, however, once an organ or tissue is damaged (state of losing function), "PRC" directly converts in situ into pluripotent stem cell and regenerate required physiological cells, tissues, and organs in situ, after which "PRC" turn back to the state of somatic cell and is latent in the tissues and organs. "PRC" is an independent entity congenital in the human body, and is the "mother" of human regenerative stem cell, as well as the standby regenerative cell for organ and tissue regeneration left by the nature when she creates the human.
Q. What is the relationship between "PRC" and the "scientific route of damaged organ regeneration"?
A. The patented "scientific route of damaged organ regeneration" is: tissue cells in human organs convert in situ into pluripotent stem cells and then regenerate new cells, tissues and tissue-organs to restore the damaged organ and function thereof. "PRC" is the original source of the regeneration, and cornerstone of this scientific route. No "PRC", no scientific route of "damaged organ regeneration".
Q. What is the difference between "PRC" and the research of embryonic stem cell line?
A. A cell line is a permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space. Many cell biologists would consider that a cell line is by definition already abnormal and that it is on the way towards becoming the culture equivalent of a neoplastic cell. The research of embryonic stem cell line is to take out the embryonic stem cell during embryonic development to establish cell line in vitro for research. As indicated in cell biology common sense, once a cell becomes a cell line, it loses its original property. In the other way, "PRC" is the study of in situ function of its own cell in the human body, belonging to the study of its own physiological regenerative function in the body. The nature of these two kinds of research is different: embryonic stem cell line is the research on experimental cell model; "PRC" is applied study on the in situ regeneration of human physiological tissues and organs by in situ somatic cells.
About Dr. Rongxiang Xu
Dr. Rongxiang Xu is the founder of "Human Body Regenerative Restoration Science" (HBRRS), a renowned life scientist and medical scientist and chairman of the board of MEBO International, a California and Beijing based intellectual property Management Company responsible for managing HBRRS. Dr. Xu is also a standing Member of the Chinese Medical Doctor Association, and Honorable Chairman of the Chinese Burn Association of the Integration of Traditional and Western Medicine.
For more information on PRC and Dr. Xu, visit www.mebo-international.com